NCT05375188View on ClinicalTrials.gov

To Evaluate if Dexmedetomidine Infusion Provides Renal Protection in Patients Undergoing Coronary Artery Bypass Graft

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

January 31, 2022

Study Completion Date

January 31, 2022

Conditions

Acute Kidney Injury

Interventions

DRUG

Dexmedetomidine

DOSAGE FORM: IV Infusion DOSAGE: 0.4 mcg/kg/hr

DRUG

Normal Saline

DOSAGE FORM: IV Infusion DOSAGE: Equal Volume

Trial Locations (1)

75100

NICVD Karachi, Karachi

All Listed Sponsors

lead

National Institute of Cardiovascular Diseases, Pakistan

OTHER

NCT05375188 - To Evaluate if Dexmedetomidine Infusion Provides Renal Protection in Patients Undergoing Coronary Artery Bypass Graft | Biotech Hunter | Biotech Hunter